Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health (NASDAQ:JAGX) announced the online availability of a presentation by Dr. Mohamad Miqdady on Short Bowel Syndrome (SBS) from the Elite Ped-GI Congress in Abu Dhabi, held from May 19-21, 2022. The presentation emphasizes the severe impacts of SBS and congenital diarrheal disorders (CDD), for which current treatment options are limited. The company’s subsidiary, Napo Therapeutics, received orphan-drug designations in the EU and the US for crofelemer, offering hope for patients. The congress aims to update healthcare professionals on pediatric gastroenterology.

Jaguar Health (NASDAQ:JAGX) announced its participation in the ACVIM Forum from June 23-25, 2022, in Austin, TX, to promote Canalevia-CA1, its FDA-conditionally approved treatment for chemotherapy-induced diarrhea in dogs. This product is crucial as many veterinarians report CID impacts chemotherapy plans, highlighting an unmet need. Canalevia-CA1 is derived from the Croton lechleri tree and offers a novel treatment option for affected dogs. The product is available through major veterinary distributors, supporting its commercial launch.

Jaguar Health (NASDAQ:JAGX) announced the publication of an article on June 8, 2022, highlighting the critical need for managing diarrhea in cancer patients, which can affect 50% to 100% of patients undergoing treatment. The article underscores that uncontrolled diarrhea can lead to significant health issues and impact patient quality of life. Jaguar's crofelemer product is in a pivotal Phase 3 trial for preventing diarrhea in adults, while its Canalevia-CA1 for dogs has conditional FDA approval. The company emphasizes the urgency of addressing this side effect for improved treatment outcomes.

Jaguar Health, Inc. (NASDAQ:JAGX) announced the approval of all four proposals at its 2022 Annual Meeting of Stockholders held on June 10, 2022. The details of the proposals are available in the definitive proxy statement filed with the SEC. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues, including Mytesi^®, which is specifically for noninfectious diarrhea in HIV/AIDS patients. The company aims to expand access to its products in Europe through its subsidiary Napo Therapeutics.

Jaguar Health (NASDAQ:JAGX) announced its participation in BIO 2022, scheduled for June 13-16, 2022, in San Diego. Karen Brunke, PhD, EVP of Corporate Development, will engage in one-on-one meetings to seek partnerships related to crofelemer, an FDA-approved treatment for diarrhea in adults with HIV/AIDS. The company aims to explore further applications for cancer therapy-related diarrhea and inflammatory bowel disease. Additionally, Jaguar is pursuing collaborations to advance its extensive library of medicinal plants and recently collaborated with Filament Health for developing botanical prescription drugs.

Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Therapeutics, has submitted an Orphan Drug Designation application for crofelemer to the European Medicines Agency (EMA) for microvillus inclusion disease (MVID), a severe congenital diarrheal disorder. This submission marks a significant step towards addressing the unmet medical need for MVID, which can cause severe complications in newborns and children. If granted, the designation offers regulatory benefits, including a 10-year market exclusivity upon approval.

Jaguar Health (NASDAQ:JAGX) presented a study on crofelemer as a potential treatment for Microvillus Inclusion Disease (MVID), a severe congenital diarrheal disorder, at Digestive Disease Week 2022. The study, led by Dr. Jay Thiagarajah, demonstrates crofelemer's potential for managing symptoms and electrolyte balance in MVID patients. This research supports Napo Therapeutics' application for Orphan Drug Designation from the European Medicines Agency. Crofelemer holds ODD for short bowel syndrome in both the EU and US.

Jaguar Health launched Take C.H.A.R.G.E., a national registry addressing canine cancer, which coincides with National Canine Cancer Awareness Day on May 23, 2022. Initial data from a Gallup Poll of over 3,500 dog owners reveal a 2.8% incidence of canine cancer—five times greater than humans. Over 80% of respondents advocate for a registry to better understand the disease. The registry aims to gather data from 35,000 canine medical records to enhance diagnosis and treatment, highlighting the need for improved canine healthcare.

Jaguar Health is hosting a media event in NYC on May 23, 2022, to launch the Canine Cancer: Take C.H.A.R.G.E. initiative, the first U.S. Canine Cancer Registry. This registry will assess cancer prevalence in dogs by analyzing anonymized medical records and survey data. The event coincides with the inaugural National Canine Cancer Awareness Day and features veterinary cancer specialists and Broadway performances. The initiative aims to improve understanding of canine cancer, benefiting both pets and potentially human health.